Laquinimod, a once-daily oral drug in development for the treatment of relapsing–remitting multiple sclerosis

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis

(2012) Giancarlo Comi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modulation of Autoimmune Demyelination by Laquinimod via Induction of Brain-Derived Neurotrophic Factor

(2011) Jan Thöne et al.   AMERICAN JOURNAL OF PATHOLOGY

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis

(2011) Jeffrey A. Cohen et al.   ANNALS OF NEUROLOGY

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway

(2011) Ralf A. Linker et al.   BRAIN

Immune mechanisms of new therapeutic strategies in MS — Teriflunomide

(2011) Malte C. Claussen et al.   CLINICAL IMMUNOLOGY

Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications

(2011) Christine Stadelmann   CURRENT OPINION IN NEUROLOGY

Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis

(2011) Jan Thöne et al.   Expert Opinion on Drug Metabolism & Toxicology

Insight into the mechanism of laquinimod action

(2011) W. Brück et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

(2011) Bhupendra Khatri et al.   LANCET NEUROLOGY

Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy

(2011) R. Hohlfeld et al.   NEUROLOGY

Development of oral immunomodulatory agents in the management of multiple sclerosis

(2011) Richard Nicholas et al.   Drug Design Development and Therapy

Emerging Oral Therapies in Multiple Sclerosis

(2010) Devon Conway et al.   Current Neurology and Neuroscience Reports

Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis

(2010) Christiane Wegner et al.   JOURNAL OF NEUROIMMUNOLOGY

Laquinimod suppress antigen presentation in relapsing–remitting multiple sclerosis: In-vitro high-throughput gene expression study

(2010) M. Gurevich et al.   JOURNAL OF NEUROIMMUNOLOGY

Pathophysiology of inflammation and tissue injury in multiple sclerosis: What are the targets for therapy

(2010) Hans Lassmann   JOURNAL OF THE NEUROLOGICAL SCIENCES

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

(2010) G. Comi et al.   Multiple Sclerosis Journal

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) G Comi et al.   LANCET

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis

(2008) M. Mehling et al.   NEUROLOGY

Strain-specific susceptibility for neurodegeneration in a rat model of autoimmune optic neuritis

(2007) Muriel B. Sättler et al.   JOURNAL OF NEUROIMMUNOLOGY